Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 45/100

Failure Rate

0.0%

0 terminated/withdrawn out of 3 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 2 completed trials have results

Key Signals

1 recruiting

Enrollment Performance

Analytics

N/A
3(100.0%)
3Total
N/A(3)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (3)

Showing 3 of 3 trials
NCT06406075Not ApplicableCompleted

Non-invasive Measurement of Glucose with Advanced Spectroscopy Techniques and Machine Learning Models

Role: lead

NCT06097689Not ApplicableCompleted

A Pilot Study to Assess the Feasibility of a Novel Non-invasive Technology to Measure Changing Blood Glucose Levels in Adults with Type-1 Diabetes Mellitus

Role: lead

NCT06272136Not ApplicableRecruiting

Liom Non-invasive Continuous Glucose Monitor "Clinical Demo" (niCGM)

Role: lead

All 3 trials loaded